Understanding Lipoprotein(a)
Lipoprotein(a), often written as Lp(a), is an independent genetic risk factor for cardiovascular disease and calcific aortic valve stenosis. Unlike standard low-density lipoprotein (LDL) cholesterol, which can be influenced by diet, exercise, and lifestyle choices, Lp(a) levels are determined almost entirely by genetics. It is estimated that approximately 20% of the global population has elevated Lp(a) levels, which can increase the risk of heart attack and stroke even in individuals with otherwise normal lipid profiles.
Structure and Composition of Lp(a)
Lp(a) consists of an LDL-like particle core containing a single molecule of Apolipoprotein B-100, which is covalently bound via a disulfide bridge to a unique glycoprotein known as apolipoprotein(a) [apo(a)]. The apo(a) protein is structurally similar to plasminogen, a key enzyme involved in dissolving blood clots. This structural similarity contributes to the distinct pathophysiological mechanisms of Lp(a).
The Pathophysiological Mechanisms of Lp(a)
Lp(a) increases cardiovascular risk through three primary mechanisms:
- Atherogenicity: Like LDL, the core of the Lp(a) particle can cross the endothelium and enter the intima of the arterial wall. Once inside, it binds to proteoglycans and becomes trapped, promoting atherosclerotic plaque development.
- Pro-inflammatory Effects: The apo(a) component of the particle binds to oxidized phospholipids. These phospholipids are highly inflammatory, stimulating endothelial cells and macrophages to release cytokines that promote arterial inflammation and calcification.
- Thrombogenicity and Anti-fibrinolysis: Because apo(a) is structurally similar to plasminogen, it competes for binding sites on fibrin and endothelial cells. However, apo(a) lacks plasminogen’s enzymatic activity, meaning it cannot dissolve clots. By blocking plasminogen binding, Lp(a) inhibits normal clot breakdown (fibrinolysis) and promotes thrombus formation.
💡 💡 Measuring Lp(a): mg/dL vs. nmol/L
Lp(a) levels should ideally be measured in nanomoles per liter (nmol/L) rather than milligrams per deciliter (mg/dL). Molar measurements count the actual number of particles, which is more accurate because the size of the apo(a) protein varies widely between individuals.
Genetics and Clinical Guidelines
Lp(a) levels are 80% to 90% determined by variations in the LPA gene on chromosome 6. This gene determines the number of repeating structures, called Kringle IV type 2 repeats, in the apo(a) protein. Individuals with fewer repeats produce smaller apo(a) proteins, which are synthesized more rapidly by the liver, leading to higher circulating Lp(a) levels. Because Lp(a) is genetically determined, levels remain stable throughout life and are not significantly altered by diet or exercise. The European Society of Cardiology (ESC) guidelines recommend measuring Lp(a) at least once in every adult’s lifetime to identify individuals with high genetic risk.
Current and Emerging Therapies
Standard lipid-lowering medications, such as statins, do not lower Lp(a) and may actually cause a minor increase in levels. For patients with elevated Lp(a), the primary clinical strategy is to lower other cardiovascular risk factors, such as LDL-C, blood pressure, and blood sugar, to reduce overall risk. PCSK9 inhibitors have been shown to lower Lp(a) by 20% to 30% by increasing clearance through the LDL receptor. Additionally, novel therapies targeting the LPA gene are currently in development. These include antisense oligonucleotides (such as pelacarsen) and small interfering RNAs (such as olpasiran and lepodisiran) designed to inhibit apo(a) synthesis in the liver. Early clinical trials have shown these therapies can reduce Lp(a) levels by over 80%.
💡 Frequently Asked Questions (FAQ)
📚 References & Sources
- Kronenberg F, et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925-3946.
- O’Donoghue ML, et al. (2022). Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (OCEAN(a)-DOSE). New England Journal of Medicine, 387(20), 1855-1864.